185 related articles for article (PubMed ID: 28824454)
21. Sexual dimorphic response to exercise in hypertrophic cardiomyopathy-associated MYBPC3-targeted knock-in mice.
Najafi A; Schlossarek S; van Deel ED; van den Heuvel N; Güçlü A; Goebel M; Kuster DW; Carrier L; van der Velden J
Pflugers Arch; 2015 Jun; 467(6):1303-17. PubMed ID: 25010737
[TBL] [Abstract][Full Text] [Related]
22. Adrenergic stress reveals septal hypertrophy and proteasome impairment in heterozygous Mybpc3-targeted knock-in mice.
Schlossarek S; Schuermann F; Geertz B; Mearini G; Eschenhagen T; Carrier L
J Muscle Res Cell Motil; 2012 May; 33(1):5-15. PubMed ID: 22076249
[TBL] [Abstract][Full Text] [Related]
23. The R21C Mutation in Cardiac Troponin I Imposes Differences in Contractile Force Generation between the Left and Right Ventricles of Knock-In Mice.
Liang J; Kazmierczak K; Rojas AI; Wang Y; Szczesna-Cordary D
Biomed Res Int; 2015; 2015():742536. PubMed ID: 25961037
[TBL] [Abstract][Full Text] [Related]
24. Investigations into the Sarcomeric Protein and Ca
Messer AE; Chan J; Daley A; Copeland O; Marston SB; Connolly DJ
Front Physiol; 2017; 8():348. PubMed ID: 28642712
[TBL] [Abstract][Full Text] [Related]
25. Green Tea Catechin Normalizes the Enhanced Ca2+ Sensitivity of Myofilaments Regulated by a Hypertrophic Cardiomyopathy-Associated Mutation in Human Cardiac Troponin I (K206I).
Warren CM; Karam CN; Wolska BM; Kobayashi T; de Tombe PP; Arteaga GM; Bos JM; Ackerman MJ; Solaro RJ
Circ Cardiovasc Genet; 2015 Dec; 8(6):765-73. PubMed ID: 26553696
[TBL] [Abstract][Full Text] [Related]
26. Pathogenesis of Hypertrophic Cardiomyopathy is Mutation Rather Than Disease Specific: A Comparison of the Cardiac Troponin T E163R and R92Q Mouse Models.
Ferrantini C; Coppini R; Pioner JM; Gentile F; Tosi B; Mazzoni L; Scellini B; Piroddi N; Laurino A; Santini L; Spinelli V; Sacconi L; De Tombe P; Moore R; Tardiff J; Mugelli A; Olivotto I; Cerbai E; Tesi C; Poggesi C
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28735292
[TBL] [Abstract][Full Text] [Related]
27. Interplay of Genotype and Substrate Stiffness in Driving the Hypertrophic Cardiomyopathy Phenotype in iPSC-Micro-Heart Muscle Arrays.
Guo J; Jiang H; Oguntuyo K; Rios B; Boodram Z; Huebsch N
Cell Mol Bioeng; 2021 Oct; 14(5):409-425. PubMed ID: 34777601
[TBL] [Abstract][Full Text] [Related]
28. Constitutive phosphorylation of cardiac myosin regulatory light chain prevents development of hypertrophic cardiomyopathy in mice.
Yuan CC; Muthu P; Kazmierczak K; Liang J; Huang W; Irving TC; Kanashiro-Takeuchi RM; Hare JM; Szczesna-Cordary D
Proc Natl Acad Sci U S A; 2015 Jul; 112(30):E4138-46. PubMed ID: 26124132
[TBL] [Abstract][Full Text] [Related]
29. Hypertrophic cardiomyopathy clinical phenotype is independent of gene mutation and mutation dosage.
Viswanathan SK; Sanders HK; McNamara JW; Jagadeesan A; Jahangir A; Tajik AJ; Sadayappan S
PLoS One; 2017; 12(11):e0187948. PubMed ID: 29121657
[TBL] [Abstract][Full Text] [Related]
30. I-1-deficiency negatively impacts survival in a cardiomyopathy mouse model.
Friedrich FW; Sotoud H; Geertz B; Weber S; Flenner F; Reischmann S; Eschenhagen T; Carrier L; El-Armouche A
Int J Cardiol Heart Vasc; 2015 Sep; 8():87-94. PubMed ID: 28785686
[TBL] [Abstract][Full Text] [Related]
31. Low expression of the K280N
Sequeira V; Wang L; Wijnker PJM; Kim K; Pinto JR; Dos Remedios C; Redwood C; Knollmann BC; van der Velden J
J Mol Cell Cardiol Plus; 2022 Sep; 1():100007. PubMed ID: 37159677
[TBL] [Abstract][Full Text] [Related]
32. Echocardiographic characterization of hypertrophic cardiomyopathy in Chinese patients with myosin-binding protein C3 mutations.
Zhao B; Wang S; Chen J; Ji Y; Wang J; Tian X; Zhi G
Exp Ther Med; 2017 Mar; 13(3):995-1002. PubMed ID: 28450932
[TBL] [Abstract][Full Text] [Related]
33. Variable cardiac myosin binding protein-C expression in the myofilaments due to MYBPC3 mutations in hypertrophic cardiomyopathy.
Parbhudayal RY; Garra AR; Götte MJW; Michels M; Pei J; Harakalova M; Asselbergs FW; van Rossum AC; van der Velden J; Kuster DWD
J Mol Cell Cardiol; 2018 Oct; 123():59-63. PubMed ID: 30170119
[TBL] [Abstract][Full Text] [Related]
34. Proteasome inhibition slightly improves cardiac function in mice with hypertrophic cardiomyopathy.
Schlossarek S; Singh SR; Geertz B; Schulz H; Reischmann S; Hübner N; Carrier L
Front Physiol; 2014; 5():484. PubMed ID: 25566086
[TBL] [Abstract][Full Text] [Related]
35. The Genetic and Molecular Bases for Hypertrophic Cardiomyopathy: The Role for Calcium Sensitization.
Ren X; Hensley N; Brady MB; Gao WD
J Cardiothorac Vasc Anesth; 2018 Feb; 32(1):478-487. PubMed ID: 29203298
[TBL] [Abstract][Full Text] [Related]
36. Pathogenic troponin T mutants with opposing effects on myofilament Ca
Dieseldorff Jones KM; Koh Y; Weller RS; Turna RS; Ahmad F; Huke S; Knollmann BC; Pinto JR; Hwang HS
Arch Biochem Biophys; 2019 Jan; 661():125-131. PubMed ID: 30445044
[TBL] [Abstract][Full Text] [Related]
37. In vivo effects of propyl gallate, a novel Ca(2+) sensitizer, in a mouse model of dilated cardiomyopathy caused by cardiac troponin T mutation.
Du CK; Zhan DY; Morimoto S
Life Sci; 2014 Jul; 109(1):15-9. PubMed ID: 24931907
[TBL] [Abstract][Full Text] [Related]
38. Prognostic predictive value of gene mutations in Japanese patients with hypertrophic cardiomyopathy.
Chida A; Inai K; Sato H; Shimada E; Nishizawa T; Shimada M; Furutani M; Furutani Y; Kawamura Y; Sugimoto M; Ishihara J; Fujiwara M; Soga T; Kawana M; Fuji S; Tateno S; Kuraishi K; Kogaki S; Nishimura M; Ayusawa M; Ichida F; Yamazawa H; Matsuoka R; Nonoyama S; Nakanishi T
Heart Vessels; 2017 Jun; 32(6):700-707. PubMed ID: 27885498
[TBL] [Abstract][Full Text] [Related]
39. Hypertrophic cardiomyopathy-linked variants of cardiac myosin-binding protein C3 display altered molecular properties and actin interaction.
Da'as SI; Fakhro K; Thanassoulas A; Krishnamoorthy N; Saleh A; Calver BL; Safieh-Garabedian B; Toft E; Nounesis G; Lai FA; Nomikos M
Biochem J; 2018 Dec; 475(24):3933-3948. PubMed ID: 30446606
[TBL] [Abstract][Full Text] [Related]
40. Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy.
Coppini R; Mazzoni L; Ferrantini C; Gentile F; Pioner JM; Laurino A; Santini L; Bargelli V; Rotellini M; Bartolucci G; Crocini C; Sacconi L; Tesi C; Belardinelli L; Tardiff J; Mugelli A; Olivotto I; Cerbai E; Poggesi C
Circ Heart Fail; 2017 Mar; 10(3):. PubMed ID: 28255011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
